US Patent

US9675549 — Tablet containing composite with cyclodextrin

Formulation · Assigned to Ambit Bioscience Corp · Expires 2033-09-30 · 7y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a tablet formulation of quizartinib dihydrochloride, a medicament for treating acute myeloid leukemia, with a specific composite of cyclodextrin.

USPTO Abstract

Provided herein is a tablet comprising, as a drug, N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof, which is a medicament for treating acute myeloid leukemia (AML), the tablet characterized by comprising a composite of N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof and hydroxypropyl-β-cyclodextrin in a ratio ranging from 1:8 to 1:20.

Drugs covered by this patent

Patent Metadata

Patent number
US9675549
Jurisdiction
US
Classification
Formulation
Expires
2033-09-30
Drug substance claim
No
Drug product claim
Yes
Assignee
Ambit Bioscience Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.